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Abstract
Background: The objective of this study was to eval-
uate the efficiency of free light chain (FLC) analysis in
comparison to serum protein electrophoresis (SPE)
for detecting M-proteinemia.
Methods: A total of 553 consecutive patients for
whom evaluation of M-proteinemia was requested
were included in this study. For all patients, serum
FLC analysis and SPE followed by pentavalent immu-
nofixation analysis was performed. Identification of
monoclonal bands was performed using specific anti-
sera. FLC analysis was performed using the Modular
P analyzer in accordance with the manufacturer’s rec-
ommendations. Local reference ranges for FLCs on
this platform were established based on samples
from patients with a normal electrophoretic pattern
wno monoclonal bands, no hypo- or hypergammaglo-
bulinemia, no acute phase pattern and normal kidney
function, i.e., estimated glomerular filtration rate
(eGFR) )60 mL/minx.
Results: Local reference ranges (95%) were estab-
lished (ns243): k: 8.01–28.26 mg/L; l: 8.07–23.58
mg/L and k/l ratio: 0.74–1.66. Negative and positive
predictive values were 98.6% and 49.5%, respectively,
for screening for M-proteinemia by SPE alone, 94.3%
and 21.7% for FLC concentration and 95.1% and
21.4% for FLC with the k/l-ratio included. Combining
protein electrophoresis and FLCs resulted in a nega-
tive predictive value of 99.0% and a positive predic-
tive value of 23.4%.
Conclusions: Serum FLC analysis alone is not suitable
for screening for M-proteinemia.
Clin Chem Lab Med 2009;47:1507–11.
Keywords: free light chain assay; immunofixation
electrophoresis; monoclonal gammopathy; M-protein-
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Introduction
Monoclonal gammopathies are characterized by clon-
al expansion of B cells that secrete intact monoclonal
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immunoglobulins, monoclonal light or heavy chains,
or both. Detection of the monoclonal immunoglobulin
or its fragments plays a central role in the diagnosis
of monoclonal gammopathies (1–3). Because of their
large size which precludes glomerular filtration,
unless there is renal damage, intact immunoglobulins
are generally found in the blood. In contrast, light
chains are readily filtered as monomers or dimers
in the glomerulus, absorbed in the proximal tubule
and catabolized within the tubular cells (4). Therefore,
light chains will appear in the urine in amounts suf-
ficient to be detected by conventional methods once
the tubular absorption mechanism is saturated. In
patients with normal renal function, light chains might
not be detected in the blood by conventional methods
(5).
For the investigation of patients suspected of having
monoclonal gammopathy, current recommendations
advise serum protein electrophoresis (SPE) followed
by immunofixation electrophoresis (IFE) using both
serum and urine (6, 7). However, such a sequalae of
investigations is laborious and time-consuming, espe-
cially when analysis is performed in batch mode. The
development of turbidimetric or nephelometric
assays for free light chains (FLCs) makes daily pro-
cessing with use of automated chemistry analyzers
possible (8). Excessive synthesis of one type of FLC
may occur in monoclonal gammopathy, not only in
FLC gammopathy (9) but often in intact immunoglob-
ulin gammopathy also (10–12). In addition, the FLC
assay is not only more sensitive than SPE and IFE for
the detection of light chain disease, but also in reveal-
ing amyloidosis (13) and non-secretory myeloma (10).
Most published studies have used the serum FLC
assays in addition to SPE and IFE (14–20), or in com-
bination with clinical information (21). Interestingly,
after reading the paper by Abadie and Bankson (22),
one might conclude that the FLC assay also could be
used for screening of monoclonal gammopathy since
the FLC assay had better positive and negative pre-
dictive values compared to SPE. Therefore, we inves-
tigated whether the FLC assay is, in addition to being
a more rapid screening tool, a more sensitive screen-
ing tool for the detection of M-proteinemia compared
with SPE alone. If correct, the FLC assay would allow
a more rapid initial screening than the present pro-
cedure with the combination of SPE and IFE.
Patients and methods
Analytical methods
SPE was performed using the SAS-3-SP-60 SB kit (prod no.:
300200, Helena Biosciences, Tyne and Wear, UK) with the
SPIFE 2000 (Helena Biosciences). This method is a split-b
method since due to the use of a high resolution gel, two
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Table 1 Locally established reference ranges and manufac-
turer’s reference ranges for free k and free l chains and the
k/l ratio.
Limit k light l light k/l ratio
chain, mg/L chain, mg/L
Local ranges
P0.5% 7.36 7.24 0.64
P2.5% 8.01 8.07 0.74
P97.5% 28.26 23.58 1.66
P99.5% 34.66 32.18 1.94
Supplier’s ranges
P2.5% 3.3 5.7 0.31
P97.5% 19.4 26.3 1.20
b-bands are obtained. IFE was performed using the SAS-3
urine analysis kit (prod no.: 300400 and 321300, Helena Bio-
sciences) for the immunofixation analysis with pentavalent
antiserum and the SAS-IFE-9 kit (prod no.: 300300 en 300301,
Helena Biosciences) for immunofixation analysis with the
specific antisera. All types of IFE were performed with the
SPIFE 2000. FLC analysis was performed using the Modular
P (Roche Diagnostics, Mannheim, Germany) and the Freelite
k and l kits (prod no.: LK016.H en LK018.H) supplied by The
Binding Site (Birmingham, UK). All analyses were performed
according to the manufacturer’s recommendations.
Reference values
For the FLC assays, the reference ranges suggested by the
supplier were derived from a study by Katzmann et al. (23).
However, the reference ranges have been shown to be
dependent on the platform used (24, 25). To establish local
reference values for the FLC assays, we selected samples
from patients with a normal pattern assessed with SPE, and
the absence of monoclonal bands in the IFE with pentavalent
antiserum. FLCs may be increased by increased production
due to stimulation of the immune system by infection or
autoimmune disease, or by reduced elimination due to renal
disease (4). In contrast, suppression of the immune system
might lead to decreased FLC concentrations. Therefore, in
addition to samples suspicious for the presence of mono-
clonal bands following SPE and IFE, samples with hypo- or
hypergammaglobulinemia (gammaglobulin -6 g/L or
)16 g/L), an acute phase pattern wa1-globulin band )3 g/L
or a C-reactive protein (CRP) )10 mg/Lx and renal dysfunc-
tion westimated glomerular filtration rate (eGFR) -60 mL/min
according to the isotope dilution mass spectrometry (IDMS)
traceble 4-variable modification of diet in renal disease
(MDRD) equationx (26, 27) were excluded for establishing
reference values. According to International Federation of
Clinical Chemistry (IFCC) recommendations, we made no
assumptions about sample distribution and used a non-par-
ametric method for establishing the 95% reference interval
(28).
Patients and samples
Serum samples (SST-tubes, prod no.: 367955, Becton Dick-
inson, Rutherford, NJ, USA) from 553 successive patients
with a request for exclusion/detection of M-proteinemia
were collected. Serum for FLC analysis and protein electro-
phoresis/IFE was frozen at –208C until analysis. Samples
from patients known to have M-proteinemia according to the
laboratory’s records were excluded.
Procedures
The efficacy of the M-protein screening was considered for
four procedures. The first M-protein screening procedure
was based on SPE alone. Results were considered positive
in cases with suspicion of monoclonal bands, deviations in
the pattern of the b-bands and hypogammaglobulinemia
(-6 g/L). In these cases, SPE was followed by immunofixa-
tion analysis. For M-protein screening based on FLCs, we
considered the procedure based on the results for FLC con-
centrations alone, and that based on the combination of FLC
concentrations with the k/l-ratio as separate procedures. For
the fourth procedure, SPE was combined with FLC analysis
(concentrationqk/l-ratio). All these screening procedures
were compared with the results of the (‘‘gold’’) standard pro-
cedure consisting of the combination of SPE and IFE with
pentavalent antiserum.
Statistical methods
Sensitivity, specificity, positive predictive value and negative
predictive value were calculated to determine the diagnostic
significance of the four screening procedures. The result of
the SPE and immunofixation analysis with the pentavalent
antiserum was used as the reference indicator (gold
standard).
Results
Reference ranges for FLCs were established from
results obtained using patient samples with a normal
pattern for SPE and IFE, as described in the Methods
section. After excluding samples from patients with
signs of infection (increased CRP/hypergammaglobu-
linemia/clinical data), renal insufficiency (eGFR
-60 mL/min) or suspicion of M-proteinemia, 243
samples were eligible for evaluation of the reference
range. P0.5%, P2.5%, P97.5% and P99.5% (95% and 99%
range) were calculated for the concentrations of k and
l FLCs as well as for the k/l-ratio. The results are
shown in Table 1 together with the reference ranges
suggested by the manufacturer.
Comparison studies
A total of 553 successive serum samples with
requests for detection/exclusion of serum M-protein-
emia were studied. The results for free k and l con-
centrations in samples from patients with renal
insufficiency, signs of infection and M-proteinemia
are shown separately in Figure 1. As expected,
patients with renal insufficiency or with signs of infec-
tion often did show increased concentrations of free
k and l, with essentially normal k/l-ratios. In patients
with monoclonal immunoglobulins one would expect
abnormal free k and l concentrations or abnormal
k/l-ratios in the majority of samples. However, Figure
1C shows that a substantial amount of the cases had
values within the reference range. The results for the
four screening procedures are displayed in Table 2.
Since SPE and immunofixation analysis do not re-
veal all the bands as being unambiguous, we divided
the samples into groups with obvious bands that can
be quantified by electrophoresis together with the
faint bands that proved to come from light chains or
immunoglobulin M, and groups with faint bands that
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Figure 1 Free k and l light chain concentrations.
In sera from patients with (A) different grades of renal insuf-
ficiency (defined by eGFR according to the MDRD calcula-
tion; , -30 mL/min and h, 30–60 mL/min), (B) signs of
infections (acute phase pattern or hypergammaglobulinemia
in serum protein electrophoresis or an elevated CRP), and
(C) various grades of M-proteinemia (, M-proteinemia
with concentration -3 g/L and d, M-proteinemia with con-
centration )3 g/L) or high suspicion of M-proteinemia (q,
hypogammaglobulinemia).
cannot be quantified with protein electrophoresis.
From the results presented in Table 2, sensitivity,
specificity and positive and negative predictive values
were calculated for the four screening procedures
(Table 3). The difference between clear and faint
bands was used for separate calculations.
Discussion
Measurement of FLCs in serum has been shown to be
useful for the diagnosis and monitoring of light chain
myeloma, non-secretory myeloma and amyloidosis.
In addition to the possible use of FLC analysis for the
diagnosis of M-proteinemia, its use is recommended
by the International Myeloma Working Group for the
monitoring of serum M-proteins (29). Since we were
intrigued by the potential use of the FLC analysis
alone as a sensitive and rapid screening tool for M-
proteinemia, as suggested in the paper from Abadie
and Bankson (22), we studied the efficiency of the
FLCs assay as a screening tool. It has been reported
previously that reference values might be platform
dependent (24, 25). Thus, as a first step, we estab-
lished local reference values using our Modular P
analyzer. The reference ranges suggested by the
supplier were based on healthy donors in whom the
presence of an M-spike was excluded by SPE and
immunofixation analysis (23). Since healthy donors
usually are not comparable to the diseased patients
our measurements are used for (e.g., with respect to
age and disease state), we, like Pattenden et al. (25),
established our reference ranges for FLCs using sam-
ples from local patients without M-proteinemia. Con-
ceptually, FLC concentrations in blood are determined
by the equilibrium between production and elimina-
tion. FLC concentrations are increased by increased
production as a consequence B-cell dyscrasias as well
as by stimulation of the immune system due to infec-
tion or autoimmune disease (illustrated in Figure 1B).
Also, decreased elimination due to renal disease
results in increased FLC concentrations; the degree of
renal failure determines the extent of increase in FLCs
(Figure 1A). Therefore, samples from patients with
renal insufficiency, as established using an eGFR -60
mL/min, and signs of infection as estimated by the
acute phase pattern in protein electrophoresis or an
increased CRP were excluded for the determination of
the reference range for FLCs. Our local reference
ranges for FLC concentrations are a little higher than
those published by Katzmann et al. (23). The major
difference is that we used selected patients while
Katzmann used healthy donors. Since Katzmann also
established slightly higher values in patients with
greater age, age might be the reason for the slightly
higher ranges we found. On the contrary, Pattenden
et al. (25) used patients for establishing reference val-
ues on two different platforms. They excluded
patients with M-proteinemia and renal insufficiency
and found different reference values using the two
platforms they used. Thus, the platform used may be
a reason for differences in reference values too. Since
our concentration range for the free light concentra-
tions starts at a higher level than that described in the
studies described earlier, we conclude that platform
differences probably play a major role in the observed
differences. However, because our reference range
has a tighter range than that reported by Pattenden,
we conclude that for the establishment of reference
values for FLCs, patients as well as apparently healthy
donors with increased production or diminished
excretion must be excluded carefully.
The main issue examined in this study was whether
the FLC assay allows for more sensitive and rapid
screening of M-proteinemia compared with SPE.
Since SPE is usually performed in batch mode, it is
time consuming. This effect is intensified by the
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Table 2 Results of four procedures for screening for M-proteinemia using serum protein electrophoresis and the free light
chains assay (k/l-ratio included as well as excluded) compared to the results according to the reference procedure (gray
colored boxes; serum protein electrophoresis combined with immunofixation analysis).
Procedure Number (%) Number (%)
Serum protein Neg.: 442 (80) Pos.: 111 (20)
electrophoresis alone Neg.: 436 (79) Pos.: 6 (1.1) Neg.: 56 (10) Pos.: 55 (9.9)
Clear bandsa: 2 Clear bandsa: 36
Faint bandsa: 4 Faint bandsa: 19
Free light chains Neg.: 369 (68) Pos.: 184 (32)
(concentration) alone Neg.: 348 (63) Pos.: 21 (3.8) Neg: 144 (26) Pos: 40 (7.2)
Clear bandsa: 11 Clear bandsa: 27
Faint bandsa: 10 Faint bandsa: 13
Free light chains Neg.: 348 (63) Pos.: 205 (37)
(concentrationqratio) Neg.: 331 (60) Pos.: 17 (3.1) Neg.: 161 (29) Pos.: 44 (8.0)
Clear bandsa: 7 Clear bandsa: 31
Faint bandsa: 10 Faint bandsa: 13
Serum protein Neg.: 306 (55) Pos.: 247 (45)
electrophoresisqfree light chains Neg.: 303 (55) Pos.: 3 (0.5) Neg.: 189 (34) Pos.: 58 (10.5)
(concentrationqratio) Clear bandsa: 0 Clear bandsa: 38
Faint bandsa: 3 Faint bandsa: 20
aMonoclonal bands were divided into clear bands, where concentration can usually be quantitated from the serum protein
electrophoresis (exceptions are light chain bands and part of the bands from the immunoglobulin M-type), and faint bands,
where concentrations can never be quantitated from serum protein electrophoresis using densitometry.
Table 3 Sensitivity, specificity and negative and positive predictive values for the 4 screening procedures for the detection/
exclusion of M-proteinemia (numbers between parentheses are the results for the clear bands only).
Procedure Sensitivity, % Specificity, % Negative Positive
predictive predictive
value, % value, %
Serum protein electrophoresis alone 90.1 (94.7) 88.6 (85.4) 98.6 (99.5) 49.5 (32.4)
Free light chains (concentration) alone 65.6 (71.1) 70.7 (69.5) 94.3 (97.0) 21.7 (14.7)
Free light chains (concentrationqratio) 72.8 (81.5) 67.3 (66.2) 95.1 (97.1) 21.4 (15.1)
Serum protein electrophoresisqfree light chains 95.0 (100) 61.6 (59.4) 99.0 (100) 23.5 (15.3)
(concentrationqratio)
sequential analysis of protein electrophoresis and IFE.
However, FLC analysis enables for more rapid analy-
sis since it can be automated easily using routine
chemistry analyzers. In addition, the FLC analysis is
much more sensitive than SPE for FLC M-proteinemia
as well as intact M-proteinemia. These two character-
istics favor FLC analysis over SPE as a screening tool
for the detection/exclusion of M-proteinemia. Accord-
ing to Abadie and Bankson (22), the positive and neg-
ative predictive value of the FLC assay (negative and
positive predictive values: 98% and 88%) was better
than that of SPE alone (negative and positive predic-
tive values: 94% and 35%). However, in our study, the
results for SPE alone (negative and positive predictive
values: 98.6% and 49.5%) are considerably better than
those for the serum FLC concentrations alone (nega-
tive and positive predictive values: 94.3% and 21.7%)
as well as for the k/l-ratio included (negative and pos-
itive predictive values: 95.11% and 21.4%). Combina-
tion of the FLC assay and SPE resulted in a negative
and positive predictive value of 99.0% and 23.5%
(Abadie and Bankson: 100% and 89%). Thus, in our
hands, FLC analysis proved to be less suitable as a
screening tool for the detection/exclusion of M-pro-
teinemia compared with SPE. Exclusion of the small
faint bands does not change these results. One can
only speculate on the reasons for these discordant
results. According to the method description, Abadie
and Bankson used an electrophoretic method with a
limited resolution. This resulted in only one b-band,
whereas we used high resolution separation with two
b-bands. Another difference might be due to differ-
ences in data interpretation. Abadie and Bankson (22)
reported a considerable number of patients as being
false positives or MGUS based on protein electropho-
resis. Apparently, they used the clinical diagnosis as
the gold standard. In our study, we considered the
presence of a monoclonal band as determined by pro-
tein electrophoresis and immunofixation analysis
with pentavalent antiserum to be the gold standard.
In our procedure, small monoclonal bands were
included in the true positive group. However, Abadie
and Bankson considered such samples to be false
positives. Combining SPE and the FLC assay did
exclude monoclonal bands of any significance. This
result is in accordance with the results of Abadie and
Bankson. Unfortunately, this excellent negative pre-
dictive value was obtained at the expense of a signif-
icant number of false positive results.
It was our objective to examine the usefulness of
the FLC assay as a screening procedure for the detec-
tion/exclusion of monoclonal bands. We conclude
Bakker et al.: Screening M-proteinemia: SPE vs. FLC 1511
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that the FLC assay could not replace SPE in the
screening for monoclonal proteins.
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